151 related articles for article (PubMed ID: 16334989)
1. Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors.
Tachedjian G; Mijch A
Sex Health; 2004; 1(2):81-9. PubMed ID: 16334989
[TBL] [Abstract][Full Text] [Related]
2. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
[TBL] [Abstract][Full Text] [Related]
7. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
[TBL] [Abstract][Full Text] [Related]
8. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.
Katzenstein DA; Bosch RJ; Hellmann N; Wang N; Bacheler L; Albrecht MA;
AIDS; 2003 Apr; 17(6):821-30. PubMed ID: 12660529
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
11. NNRTI hypersusceptibility.
Delgado J; Shulman N
AIDS Read; 2005 Jan; 15(1):28-30, 32-4. PubMed ID: 15685732
[TBL] [Abstract][Full Text] [Related]
12. The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage?
Zaccarelli M; Tozzi V; Perno CF; Antinori A
Curr HIV Res; 2004 Jul; 2(3):283-92. PubMed ID: 15279592
[TBL] [Abstract][Full Text] [Related]
13. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
Moyo S; Gaseitsiwe S; Zahralban-Steele M; Maruapula D; Nkhisang T; Mokaleng B; Mohammed T; Ditlhako TR; Bareng OT; Mokgethi TP; van Widenfelt E; Pretorius-Holme M; Mine MO; Raizes E; Yankinda EK; Wirth KE; Gaolathe T; Makhema JM; Lockman S; Essex M; Novitsky V
AIDS; 2019 May; 33(6):1073-1082. PubMed ID: 30946161
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
[TBL] [Abstract][Full Text] [Related]
15. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.
Haubrich RH; Kemper CA; Hellmann NS; Keiser PH; Witt MD; Forthal DN; Leedom J; Leibowitz M; Whitcomb JM; Richman D; McCutchan JA;
AIDS; 2002 Oct; 16(15):F33-40. PubMed ID: 12370520
[TBL] [Abstract][Full Text] [Related]
16. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.
Hofstra LM; Sauvageot N; Albert J; Alexiev I; Garcia F; Struck D; Van de Vijver DAMC; Åsjö B; Beshkov D; Coughlan S; Descamps D; Griskevicius A; Hamouda O; Horban A; Van Kasteren M; Kolupajeva T; Kostrikis LG; Liitsola K; Linka M; Mor O; Nielsen C; Otelea D; Paraskevis D; Paredes R; Poljak M; Puchhammer-Stöckl E; Sönnerborg A; Staneková D; Stanojevic M; Van Laethem K; Zazzi M; Zidovec Lepej S; Boucher CAB; Schmit JC; Wensing AMJ; ; Puchhammer-Stockl E; Sarcletti M; Schmied B; Geit M; Balluch G; Vandamme AM; Vercauteren J; Derdelinckx I; Sasse A; Bogaert M; Ceunen H; De Roo A; De Wit S; Echahidi F; Fransen K; Goffard JC; Goubau P; Goudeseune E; Yombi JC; Lacor P; Liesnard C; Moutschen M; Pierard D; Rens R; Schrooten Y; Vaira D; Vandekerckhove LPR; Van den Heuvel A; Van Der Gucht B; Van Ranst M; Van Wijngaerden E; Vandercam B; Vekemans M; Verhofstede C; Clumeck N; Van Laethem K; Beshkov D; Alexiev I; Lepej SZ; Begovac J; Kostrikis L; Demetriades I; Kousiappa I; Demetriou V; Hezka J; Linka M; Maly M; Machala L; Nielsen C; Jørgensen LB; Gerstoft J; Mathiesen L; Pedersen C; Nielsen H; Laursen A; Kvinesdal B; Liitsola K; Ristola M; Suni J; Sutinen J; Descamps D; Assoumou L; Castor G; Grude M; Flandre P; Storto A; Hamouda O; Kücherer C; Berg T; Braun P; Poggensee G; Däumer M; Eberle J; Heiken H; Kaiser R; Knechten H; Korn K; Müller H; Neifer S; Schmidt B; Walter H; Gunsenheimer-Bartmeyer B; Harrer T; Paraskevis D; Hatzakis A; Zavitsanou A; Vassilakis A; Lazanas M; Chini M; Lioni A; Sakka V; Kourkounti S; Paparizos V; Antoniadou A; Papadopoulos A; Poulakou G; Katsarolis I; Protopapas K; Chryssos G; Drimis S; Gargalianos P; Xylomenos G; Lourida G; Psichogiou M; Daikos GL; Sipsas NV; Kontos A; Gamaletsou MN; Koratzanis G; Sambatakou H; Mariolis H; Skoutelis A; Papastamopoulos V; Georgiou O; Panagopoulos P; Maltezos E; Coughlan S; De Gascun C; Byrne C; Duffy M; Bergin C; Reidy D; Farrell G; Lambert J; O'Connor E; Rochford A; Low J; Coakely P; O'Dea S; Hall W; Mor O; Levi I; Chemtob D; Grossman Z; Zazzi M; de Luca A; Balotta C; Riva C; Mussini C; Caramma I; Capetti A; Colombo MC; Rossi C; Prati F; Tramuto F; Vitale F; Ciccozzi M; Angarano G; Rezza G; Kolupajeva T; Vasins O; Griskevicius A; Lipnickiene V; Schmit JC; Struck D; Sauvageot N; Hemmer R; Arendt V; Michaux C; Staub T; Sequin-Devaux C; Wensing AMJ; Boucher CAB; van de Vijver DAMC; van Kessel A; van Bentum PHM; Brinkman K; Connell BJ; van der Ende ME; Hoepelman IM; van Kasteren M; Kuipers M; Langebeek N; Richter C; Santegoets RMWJ; Schrijnders-Gudde L; Schuurman R; van de Ven BJM; Åsjö B; Kran AB; Ormaasen V; Aavitsland P; Horban A; Stanczak JJ; Stanczak GP; Firlag-Burkacka E; Wiercinska-Drapalo A; Jablonowska E; Maolepsza E; Leszczyszyn-Pynka M; Szata W; Camacho R; Palma C; Borges F; Paixão T; Duque V; Araújo F; Otelea D; Paraschiv S; Tudor AM; Cernat R; Chiriac C; Dumitrescu F; Prisecariu LJ; Stanojevic M; Jevtovic D; Salemovic D; Stanekova D; Habekova M; Chabadová Z; Drobkova T; Bukovinova P; Shunnar A; Truska P; Poljak M; Lunar M; Babic D; Tomazic J; Vidmar L; Vovko T; Karner P; Garcia F; Paredes R; Monge S; Moreno S; Del Amo J; Asensi V; Sirvent JL; de Mendoza C; Delgado R; Gutiérrez F; Berenguer J; Garcia-Bujalance S; Stella N; de Los Santos I; Blanco JR; Dalmau D; Rivero M; Segura F; Elías MJP; Alvarez M; Chueca N; Rodríguez-Martín C; Vidal C; Palomares JC; Viciana I; Viciana P; Cordoba J; Aguilera A; Domingo P; Galindo MJ; Miralles C; Del Pozo MA; Ribera E; Iribarren JA; Ruiz L; de la Torre J; Vidal F; Clotet B; Albert J; Heidarian A; Aperia-Peipke K; Axelsson M; Mild M; Karlsson A; Sönnerborg A; Thalme A; Navér L; Bratt G; Karlsson A; Blaxhult A; Gisslén M; Svennerholm B; Bergbrant I; Björkman P; Säll C; Mellgren Å; Lindholm A; Kuylenstierna N; Montelius R; Azimi F; Johansson B; Carlsson M; Johansson E; Ljungberg B; Ekvall H; Strand A; Mäkitalo S; Öberg S; Holmblad P; Höfer M; Holmberg H; Josefson P; Ryding U
Clin Infect Dis; 2016 Mar; 62(5):655-663. PubMed ID: 26620652
[TBL] [Abstract][Full Text] [Related]
17. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
[TBL] [Abstract][Full Text] [Related]
19. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
Ceccherini-Silberstein F; Svicher V; Sing T; Artese A; Santoro MM; Forbici F; Bertoli A; Alcaro S; Palamara G; d'Arminio Monforte A; Balzarini J; Antinori A; Lengauer T; Perno CF
J Virol; 2007 Oct; 81(20):11507-19. PubMed ID: 17686836
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
